In its latest quarterly disclosure, Femto Technologies reported a revenue decline driven by lower software development sales and foreign exchange headwinds, while highlighting the commencement of revenues from its new core CRM platform launched in 2023. The cannabis-specific CRM platform is undergoing testing with no immediate revenue expectancy, and the medical cannabis facility project remains on hold. The company’s business model centers on specialized CRM software for SMEs with high reliance on a single major customer accounting for roughly 80% of sales. Although liquidity strength remains notable, customer concentration coupled with foreign currency exposure and net losses present ongoing challenges. Key near-term milestones include validation of the cannabis CRM solution and expansion of the Sensera device pipeline.